{"id":10713,"date":"2018-07-16T13:04:19","date_gmt":"2018-07-16T05:04:19","guid":{"rendered":"https:\/\/id-ea.org\/tbe\/?p=10713"},"modified":"2019-06-18T15:58:00","modified_gmt":"2019-06-18T07:58:00","slug":"snapshot-week-29","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/","title":{"rendered":"Snapshot \u2013 Week 29"},"content":{"rendered":"<span class=\"cb-itemprop\" itemprop=\"reviewBody\"><p>Haviernik et al.<br \/>\nArbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses.<br \/>\nViruses 2018; 10: 184; doi:10.3390\/v10040184<\/p>\n<p>About 25 years ago, Arbidol (also known as Umifenovir), a broad-spectrum antiviral compound, has been developed in Russia. This drug is licensed in Russia and China for the prophylaxis and treatment of human influenza A and B infections. Subsequently, Arbidol was shown to be active against various DNA and RNA and enveloped and non-enveloped viruses. Arbidol can intercalate into membrane lipids and inhibits membrane fusion between virus particles and the membranes of endosomes. The authors have evaluated the action of Arbidol on various flaviviruses and have used the strain Hypr as representative for the European subtype of the TBE virus. TBE virus infections were susceptible to Arbidol when propagated in HBCA (human brain cortical astrocytes) and Vero cells in a dose-dependent manner with EC50 values of 18.67 uM. Virus replication was incomplete when 25 and 50 uM Arbidol were used in either HBCA or Vero cells respectively, and the viral titer was reduced 1000-fold compared to non-treated cells. These data broaden the possibility for future in vivo testing of Arbidol in animal models of the TBE virus and other flavivirus infections.<\/p>\n<\/span>","protected":false},"excerpt":{"rendered":"<p>Haviernik et al. Arbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses 2018; 10: 184; doi:10.3390\/v10040184 About 25 years ago, Arbidol (also known as Umifenovir), a broad-spectrum antiviral compound, has been developed in Russia. This drug is licensed in Russia and China for the prophylaxis and treatment of human influenza A and B infections. Subsequently, Arbidol was shown to be active against various DNA and RNA and enveloped and non-enveloped viruses. Arbidol can intercalate into membrane lipids and inhibits membrane fusion between virus particles and the membranes of endosomes. The authors have evaluated the action of Arbidol on various flaviviruses and have used the strain Hypr as representative for the European subtype of the TBE virus. TBE virus infections were susceptible to Arbidol when propagated in HBCA (human brain cortical astrocytes) and Vero cells in a dose-dependent manner with EC50 values of 18.67 uM. Virus replication was incomplete when 25 and 50 uM Arbidol were used in either HBCA or Vero cells respectively, and the viral titer was reduced 1000-fold compared to non-treated cells. These data broaden the possibility for future in vivo testing of Arbidol in animal models of the TBE virus and other flavivirus infections.<\/p>\n","protected":false},"author":6,"featured_media":12864,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[18],"tags":[],"coauthors":[81],"class_list":["post-10713","post","type-post","status-publish","format-standard","has-post-thumbnail","category-snapshot"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Snapshot \u2013 Week 29 - TBE Book<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snapshot \u2013 Week 29 - TBE Book\" \/>\n<meta property=\"og:description\" content=\"Haviernik et al. Arbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses 2018; 10: 184; doi:10.3390\/v10040184 About 25 years ago, Arbidol (also known as Umifenovir), a broad-spectrum antiviral compound, has been developed in Russia. This drug is licensed in Russia and China for the prophylaxis and treatment of human influenza A and B infections. Subsequently, Arbidol was shown to be active against various DNA and RNA and enveloped and non-enveloped viruses. Arbidol can intercalate into membrane lipids and inhibits membrane fusion between virus particles and the membranes of endosomes. The authors have evaluated the action of Arbidol on various flaviviruses and have used the strain Hypr as representative for the European subtype of the TBE virus. TBE virus infections were susceptible to Arbidol when propagated in HBCA (human brain cortical astrocytes) and Vero cells in a dose-dependent manner with EC50 values of 18.67 uM. Virus replication was incomplete when 25 and 50 uM Arbidol were used in either HBCA or Vero cells respectively, and the viral titer was reduced 1000-fold compared to non-treated cells. These data broaden the possibility for future in vivo testing of Arbidol in animal models of the TBE virus and other flavivirus infections.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2018-07-16T05:04:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-06-18T07:58:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Michael Br\u00f6ker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael Br\u00f6ker\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/\"},\"author\":{\"name\":\"augustine\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2f903afeb7534df7457d2e3f6d30f64c\"},\"headline\":\"Snapshot \u2013 Week 29\",\"datePublished\":\"2018-07-16T05:04:19+00:00\",\"dateModified\":\"2019-06-18T07:58:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/\"},\"wordCount\":197,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"articleSection\":[\"Snapshot\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/\",\"name\":\"Snapshot \u2013 Week 29 - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"datePublished\":\"2018-07-16T05:04:19+00:00\",\"dateModified\":\"2019-06-18T07:58:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"width\":1180,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Snapshot \u2013 Week 29\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2f903afeb7534df7457d2e3f6d30f64c\",\"name\":\"augustine\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=ge035e25b3672069f7222fdb9b71e7000\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=g\",\"caption\":\"augustine\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/augustine-augustine\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Snapshot \u2013 Week 29 - TBE Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/","og_locale":"en_US","og_type":"article","og_title":"Snapshot \u2013 Week 29 - TBE Book","og_description":"Haviernik et al. Arbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses 2018; 10: 184; doi:10.3390\/v10040184 About 25 years ago, Arbidol (also known as Umifenovir), a broad-spectrum antiviral compound, has been developed in Russia. This drug is licensed in Russia and China for the prophylaxis and treatment of human influenza A and B infections. Subsequently, Arbidol was shown to be active against various DNA and RNA and enveloped and non-enveloped viruses. Arbidol can intercalate into membrane lipids and inhibits membrane fusion between virus particles and the membranes of endosomes. The authors have evaluated the action of Arbidol on various flaviviruses and have used the strain Hypr as representative for the European subtype of the TBE virus. TBE virus infections were susceptible to Arbidol when propagated in HBCA (human brain cortical astrocytes) and Vero cells in a dose-dependent manner with EC50 values of 18.67 uM. Virus replication was incomplete when 25 and 50 uM Arbidol were used in either HBCA or Vero cells respectively, and the viral titer was reduced 1000-fold compared to non-treated cells. These data broaden the possibility for future in vivo testing of Arbidol in animal models of the TBE virus and other flavivirus infections.","og_url":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/","og_site_name":"TBE Book","article_published_time":"2018-07-16T05:04:19+00:00","article_modified_time":"2019-06-18T07:58:00+00:00","og_image":[{"width":1180,"height":250,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","type":"image\/jpeg"}],"author":"Michael Br\u00f6ker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Michael Br\u00f6ker","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/"},"author":{"name":"augustine","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2f903afeb7534df7457d2e3f6d30f64c"},"headline":"Snapshot \u2013 Week 29","datePublished":"2018-07-16T05:04:19+00:00","dateModified":"2019-06-18T07:58:00+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/"},"wordCount":197,"commentCount":0,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","articleSection":["Snapshot"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/tbenews.com\/tbe\/snapshot-week-29\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/","url":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/","name":"Snapshot \u2013 Week 29 - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","datePublished":"2018-07-16T05:04:19+00:00","dateModified":"2019-06-18T07:58:00+00:00","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/snapshot-week-29\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","width":1180,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"Snapshot \u2013 Week 29"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2f903afeb7534df7457d2e3f6d30f64c","name":"augustine","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=ge035e25b3672069f7222fdb9b71e7000","url":"https:\/\/secure.gravatar.com\/avatar\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/81a51e276681ab241e1fba1ee7f85ca6fcd68b139ab41edba2d0442a923df1f6?s=96&d=mm&r=g","caption":"augustine"},"url":"https:\/\/tbenews.com\/tbe\/author\/augustine-augustine\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/10713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=10713"}],"version-history":[{"count":2,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/10713\/revisions"}],"predecessor-version":[{"id":13326,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/10713\/revisions\/13326"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/12864"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=10713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=10713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=10713"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=10713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}